Live Feeds
● LIVE Updated 2h ago · 12 sources tracked

Breakthrough vaccine for the deadliest skin cancer cut risk by almost half

A personalized mRNA vaccine developed by Merck and Moderna significantly reduces the risk of death or recurrence for patients with melanoma, the deadliest form of skin cancer. Late-stage trial results show the experimental treatment cut the risk of the disease returning or resulting in death by 42 percent. The therapeutic approach targets the recurrence of tumors in melanoma patients, offering a promising new direction in skin cancer therapy. While the data signals a major medical advancement, the release of detailed trial statistics on social media also triggered a drop in Moderna shares.

🎙️

Listen to Live Briefing

Real-time synthesized voice briefing · Live Feeds Desk

⏱ ~3 min
Speed:
RSS Source map (12)
⚡ Key Developments & Real-Time Context
Text size:
  • ✓ A personalized mRNA cancer vaccine developed by Merck and Moderna cut the risk of melanoma death or recurrence by 42 percent.
  • ✓ Late-stage trial results showed the experimental vaccine slashed the risk that melanoma returns.
  • ✓ Moderna shares plummeted after cancer-vaccine data was shared on social media.
🛡️ Source Corroboration: 12 independent reporting domains (95% confidence) ⏱ Read time: ~2 min

What changed

Trial data revealing that the personalized mRNA cancer vaccine cut the risk of melanoma death or recurrence by 42 percent was shared publicly.

Live updates

  1. Melanoma Vaccine Cuts Risk of Death or Recurrence by 42 Percent

    A personalized mRNA vaccine developed by Merck and Moderna significantly reduces the risk of death or recurrence for patients with melanoma, the deadliest form of skin cancer. Late-stage trial results show the experimental treatment cut the risk of the disease returning or resulting in death by 42 percent. The therapeutic approach targets the recurrence of tumors in melanoma patients, offering a promising new direction in skin cancer therapy. While the data signals a major medical advancement, the release of detailed trial statistics on social media also triggered a drop in Moderna shares.

    Why it matters

    Melanoma remains one of the most dangerous and aggressive forms of skin cancer, making recurrence a primary concern for patients following initial treatment. The development of personalized mRNA vaccines represents a shift toward customized immunotherapies designed to train a patient's immune system to recognize and attack specific cancer cells. The positive late-stage trial results highlight the growing intersection of mRNA technology and oncology.

    What is confirmed

    • A personalized mRNA cancer vaccine developed by Merck and Moderna cut the risk of melanoma death or recurrence by 42 percent.
    • Late-stage trial results showed the experimental vaccine slashed the risk that melanoma returns.
    • Moderna shares plummeted after cancer-vaccine data was shared on social media.

    What to watch next

    • Further peer-reviewed publication of the full late-stage trial dataset
    • Market and regulatory response to the social media data release
    Sources used for this update (12)
    1. www.bbc.com — BBC Home - Breaking News, World News, US News, Sports, Business...
    2. help.naver.com — Futures Flat As Oil Rebounds After Trump's "Energy Ceasefire" Unravels, Memory Stocks Slide | ZeroHedge
    3. WSJ — Moderna’s Shares Plummet After Cancer-Vaccine Data Shared on Social Media
    4. Reuters — Merck/Moderna cancer vaccine cuts risk of death or recurrence from melanoma by over 40%
    5. The Washington Post — Breakthrough vaccine for the deadliest skin cancer cut risk by almost half
    6. arstechnica.com — Moderna and Merck say their mRNA cancer vaccine cut death, recurrence by 42%
    7. BBC — World first personalised cancer vaccine stops disease returning in major trial
    8. Yahoo — A novel mRNA cancer vaccine helps reduce the chances of melanoma patients' tumors returning
    9. Phys.org — Canine cancer patients contribute to next-generation minimally invasive cancer therapies for dogs and humans
    10. www.indailysa.com.au — Skin cancer breakthrough could cut death risk by almost half
    11. abcnews.com — Breakthrough cancer vaccine reduces melanoma from returning ...
    12. dnyuz.com — Breakthrough vaccine for the deadliest skin cancer cut risk ...
    confidence 95%
📊

Community Sentiment: How do you assess this situation?

Voice your perspective · Real-time aggregated sentiment from the Live Feeds community